• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    • The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.
    • Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1
    • Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1
    • Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1
    • Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are pioneering the fight against itch, calling on other veterinarians to help America's itchy dogs find cost-effective itch relief and long-lasting solutions.

    GREENFIELD, Ind., June 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today released a new report highlighting the significance of America's Itchy Dogs and the impact itch has on dogs, their owners, and veterinarians. The first-of-its-kind report includes findings from multiple surveys of pet owners, as well as veterinarians, and reveals startling details on how badly dogs around the country are itching for relief and cost-effective, long-lasting solutions. With Zenrelia™ (ilunocitinib tablets) now widely available as a once-daily, cost-effective solution, veterinarians and dog owners have another option to help dogs get back to normal.

    Veterinarians and pet owners are frustrated by itch.

    "There are more itchy dogs out there than you might realize," said Dr. Jennifer Miller, veterinarian and canine dermatology expert at Elanco. "This report shows that nearly 9 in 10 U.S. dogs are 'itchy dogs,' according to their pet owners, experiencing symptoms of itchiness at any point throughout the year. Seasonal allergies make that worse, with more than 8 in 10 dog owners saying that their cities' pollen levels affect their dogs' itch levels. On average, pet owners say they're spending $173 more and using two additional treatments to treat their dogs' itch during allergy season; and they're desperate for a simple, cost-effective solution." 1

    Veterinarians and Dog Owners Alike Are Frustrated by Itch

    Itching is one of the top reasons dogs are brought to the veterinarian, and it's a frustrating issue for both dog owners and veterinarians alike.2 The new report finds that itchy dog owners on average wait 6 weeks after their dog has started showing symptoms of itch to take them to the veterinarian.2 Ninety percent of veterinarians say that itchy dog owners wait too long before bringing their dog, resulting in raw and infected skin and also an irritated dog owner who wants their dog to experience relief quickly.3 If a veterinarian can't scratch that itch quickly, pet owners will find one who can. Nearly 8 in 10 itchy dog owners who have switched veterinarians report switching after 3 visits or less.2 Switching veterinarians isn't the only extreme circumstance that owners of itchy dogs are willing to take – about half of dog owners say having an itchy dog tests their resolve to have a dog at all. Some say they'd be willing to move to a new city if it was going to help their dog's extreme itch.1

    The report shows that a majority of itchy dog owners crave simplicity and long-lasting relief. When it comes to treating an itchy dog, the majority of dog owners want to give one pill a day compared to multiple pills per day.2 In 2024, 75% of dog owners said that they need more affordable options to stop their dogs' itch. 1

    "These findings highlight the critical need for veterinarians to be an ally in the fight against itch and to deliver effective results by the second visit," says Dr. Joya Griffin, veterinarian and board-certified dermatologist at Animal Dermatology Clinic in Louisville. "Itching doesn't just affect the dog; it can have a significant impact on the whole family. Having the right tools is critical for alleviating the itch and discomfort both seasonally and year-around. I've recently started using Zenrelia in my clinic and have seen firsthand how this once-daily, cost-effective treatment can provide much needed relief during allergy season and for refractory patients who suffer year round."

    Dogs should be up to date on vaccinations prior to starting Zenrelia. It's important to read the package insert, including the full Boxed Warning regarding concurrent vaccine administration, or speak with your veterinarian before use.

    The data also revealed there are a lot of emotions tied to an itchy dog – 53%1 of itchy dog owners report feeling judged by someone in their community for having an itchy dog and 75% feel hopeless when their veterinarian is unable to treat their itchy dog.1

    "As a veterinary dermatologist, I've seen the emotional toll having an itchy dog can take on pet owners. Many of my clients have invested significant time and resources on multiple treatment options that often times do not provide relief for their pet," said Dr. Andrew Rosenberg, veterinarian and President of the American College of Veterinary Dermatology (AVCD). "Now with Zenrelia, I have another great tool in my treatment toolbox that allows me to prescribe a simple, cost-effective solution that provides the relief both dogs and their owners have been craving."

    After finding successful treatment for itchy dogs, veterinarians and pet owners have a stronger bond than ever. In fact, 84% of veterinarians say that dog owners are more likely to visit for other issues with their dog and 70% of dog owners refer other dog owners to their office.3

    "I've seen how helping the dog find zen also increases the bond with my clients," said Dr. Tom Lewis, veterinarian and board-certified dermatologist at Dermatology Animals in Gilbert. "Often times, by the time the dog owner gets to me, they're just as frustrated as the dog is. Now, I know I have a treatment option that I can try that gets both dogs and their owners back to zen; that's why I'm encouraging other veterinarians to join us in becoming allies against itch."

    The Highest Human Allergy Cities Have More Itchy Dogs

    For dog owners and veterinarians who live in the highest human allergy cities in the country, they may be seeing more itchy dogs.1,4 In fact, 85% of dogs in the Allergy and Asthma Foundation's top U.S. allergy capitals experience itch during allergy season, compared to 79% of all U.S. dogs.1 

    The deep dive into these cities, also appropriately called "America's Itchiest Cities," highlights some unique differences in each city and state. For example:1

    • Wichita, KS itchy dog owners are more likely than U.S. dog owners to feel financially burdened when they have to go to a veterinarian to treat their itchy dog.
    • New Orleans, LA has the itchiest dogs year-round.
    • Oklahoma City, OK itchy dog owners are on the hunt for the best treatment.
    • Tulsa, OK itchy dog owners feel the financial strain of trying different treatments more than U.S. dog owners in general.
    • Memphis, TN itchy dog owners are doing the most and spending the most, spending a whopping $548 year-round to treat their dogs' itchiness compared to $302 for U.S. dog owners.
    • Little Rock, AR itchy dog owners report fewer visits to their veterinarian but have tried just as many treatments.
    • Raleigh, NC itchy dog owners are the least judgmental of itchiness.
    • Richmond, VA itchy dog owners are going above and beyond, more likely to seek out a specialist.
    • Greenville, SC itchy dog owners are the most likely to feel compassionate when it comes to itch.
    • Greensboro, NC itchy dogs feel the itch even longer with an extended allergy season.

    Dr. Emily Roberson, veterinarian at Animal Hospital of East Davie just outside of Greensboro, NC, says that she's seen a number of itchy dogs this year and has been relieved to have another treatment option. "Here in North Carolina, we're right in the thick of allergy season, and my clinic has seen an influx of itchy dogs. It's truly heartbreaking to see these pets so uncomfortable. That's why I'm thrilled to have Zenrelia as a treatment option to offer these itchy dogs, and their owners, much-needed comfort."

    For additional information, resources, and to learn more about America's Itchy Dogs visit www.ItchyDogs.com.

    *Drs. Griffin, Rosenberg, and Lewis are consultants for Elanco Animal Health.

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com. 

    INDICATIONS

    Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age. 

    IMPORTANT SAFETY INFORMATION

    See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia. 

    WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs. 

    © 2025 Elanco or its affiliates: Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

    PM-US-25-1076

    1 Elanco Animal Health. Data on File

    2 Elanco Animal Health. Data on File

    3 Elanco Animal Health. Data on File

    4 *Allergy Capital dog owners / dogs refers to all respondents living in one of the top 10 allergy DMAs: Wichita, KS; New Orleans, LA; Oklahoma City, OK; Tulsa, OK; Memphis, TN; Little Rock, AR; Raleigh, NC; Richmond, VA; Greenville, SC; Greensboro, NC

    Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com

    Media Contact: Season Solorio (765) 316-0233 season.solorio@elancoah.com

    America's Itchiest Cities

    Elanco logo (PRNewsfoto/Elanco Animal Health)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-releases-new-report-highlighting-the-significance-of-americas-itchy-dogs-and-the-need-for-itch-relief-302474271.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    4/15/2026$30.00Buy
    Citigroup
    1/22/2026Neutral → Overweight
    Piper Sandler
    12/9/2025$30.00Overweight
    Barclays
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    11/19/2025$25.00Hold → Buy
    Argus
    10/7/2025$24.00Neutral → Overweight
    Analyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ELAN
    SEC Filings

    View All

    SEC Form SD filed by Elanco Animal Health Incorporated

    SD - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:09:19 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:00:57 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health Incorporated

    SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    5/14/26 12:30:54 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm

    Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today reaffirms its commitment to providing veterinarians, livestock produ

    6/4/26 6:26:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience

    INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry. According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.Stable Expectations for Pet Owner Spend:

    6/3/26 7:26:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

    Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics todayBefrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmabStarts controlling itch within 24 hours and is given as an in-clinic injectionSelect Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomesMeet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their jo

    5/18/26 7:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Elanco Animal Health with a new price target

    Citigroup initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $30.00

    4/15/26 8:08:24 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/2/26 5:12:01 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/2/26 5:11:34 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/2/26 5:10:50 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Modi Rajeev A. bought $99,939 worth of shares (4,911 units at $20.35), increasing direct ownership by 3% to 160,812 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:39:20 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $99,843 worth of shares (4,971 units at $20.09) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:38:26 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Animal Health Reports First Quarter 2026 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y

    5/6/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.asp

    4/16/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care